日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers

CGRP结合单克隆抗体LY2951742(Galcanezumab)在健康志愿者中的安全性、耐受性、药代动力学和药效学研究

Monteith, David; Collins, Emily C; Vandermeulen, Corinne; Van Hecken, Anne; Raddad, Eyas; Scherer, Joel C; Grayzel, David; Schuetz, Thomas J; de Hoon, Jan

Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study

循环肿瘤细胞和CXCR4表达作为CXCR4肽拮抗剂联合卡铂-依托泊苷治疗小细胞肺癌的生物标志物的预后和预测价值:一项II期研究的探索性分析

Salgia, Ravi; Weaver, R Waide; McCleod, Michael; Stille, John R; Yan, S Betty; Roberson, Stephanie; Polzer, John; Flynt, Amy; Raddad, Eyas; Peek, Victoria L; Wijayawardana, Sameera R; Um, Suzane L; Gross, Steve; Connelly, Mark C; Morano, Carrie; Repollet, Madeline; Sanders, Renouard; Baeten, Kurt; D'Haese, David; Spigel, David R

Distinct mobilization of leukocytes and hematopoietic stem cells by CXCR4 peptide antagonist LY2510924 and monoclonal antibody LY2624587.

CXCR4肽拮抗剂LY2510924和单克隆抗体LY2624587可显著动员白细胞和造血干细胞

Peng Sheng-Bin, Van Horn Robert D, Yin Tinggui, Brown Robin M, Roell William C, Obungu Victor H, Ruegg Charles, Wroblewski Victor J, Raddad Eyas, Stille John R

Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrations

多次静脉和皮下给药后LY2189102的群体药代动力学模型

Bihorel, Sébastien; Fiedler-Kelly, Jill; Ludwig, Elizabeth; Sloan-Lancaster, Joanne; Raddad, Eyas